Stock listing
Frankfurt:VX1 Vertex Pharmaceuticals Incorporated Aktie
German listing (Frankfurt) of Vertex Pharmaceuticals Incorporated · home listing NASDAQ:VRTX
Follow Vertex Pharmaceuticals Incorporated into a list and get an email when it puts out news.
Share price · FWB:VX1
€477.05 EUR -2.95 (-0.6%)
Close on Nov 20, 2026
- Day range
- €469.40 – €477.75 EURNov 20, 2026
- Volume
- 149 sharesNov 20, 2026
- Market cap
- €121.1B EURAt the close on Nov 20, 2026 · price × 253.8M shares outstanding
- 52-week range
- €351.98 – €501.47 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €64,948 EURMedian day 73 shares · 5 days with no trades · last 3 months, Aug 20, 2026 – Nov 13, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VRTX · Home | $515.02 USD | -21.43 (-4.0%) | 1,767,642 | $529.94 | $531.37 | $513.80 | $536.45 | Close on Nov 20, 2026 |
| BMV:VRTX | $9,936.00 MXN | +11.00 (+0.1%) | 52 | $9,936.00 | $9,936.00 | $9,936.00 | $9,925.00 | Close on Nov 20, 2026 |
| B3:VRTX34 | 96.41 BRL | -1.91 (-1.9%) | 646 | 98.70 | 98.70 | 96.31 | 98.32 | Close on Nov 19, 2026 |
| LSE:0QZU | $520.00 USD | -1.59 (-0.3%) | 1,492 | $520.30 | $537.99 | $510.00 | $521.59 | Close on Nov 20, 2026 |
| Frankfurt:VX1 | €477.05 EUR | -2.95 (-0.6%) | 149 | €469.40 | €477.75 | €469.40 | €480.00 | Close on Nov 20, 2026 |
| Dusseldorf:VX1 | €474.10 EUR | -1.20 (-0.3%) | — | €473.50 | €477.85 | €473.50 | €475.30 | Close on Nov 20, 2026 |
| Munich:VX1 | €474.00 EUR | -16.80 (-3.4%) | — | €479.00 | €479.00 | €474.00 | €490.80 | Close on Nov 20, 2026 |
| Hamburg:VX1 | €477.45 EUR | +0.75 (+0.2%) | — | €474.00 | €477.45 | €474.00 | €476.70 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 13, 2026 · FWB:VX1 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €487.02 | -2.024 | -0.4% | €487.37 | €487.83 | €485.79 | 143 | |
| €489.05 | -3.597 | -0.7% | €490.53 | €490.75 | €488.79 | 15 | |
| €492.64 | +2.704 | +0.6% | €495.18 | €495.36 | €492.64 | 304 | |
| €489.94 | +0.327 | +0.1% | €489.94 | €489.94 | €489.94 | 270 | |
| €489.61 | +9.018 | +1.9% | €489.66 | €490.86 | €489.33 | 330 | |
| €480.60 | -12.33 | -2.5% | €481.80 | €490.98 | €477.49 | 330 | |
| €492.92 | +6.508 | +1.3% | €487.20 | €493.33 | €482.38 | 9 | |
| €486.41 | +5.24 | +1.1% | €474.75 | €488.52 | €472.54 | 842 | |
| €481.17 | -14.31 | -2.9% | €497.18 | €500.54 | €479.00 | 0 | |
| €495.48 | -5.519 | -1.1% | €495.48 | €495.48 | €495.48 | 320 | |
| €501.00 | +18.36 | +3.8% | €490.50 | €501.47 | €490.47 | 1,226 | |
| €482.65 | +3.67 | +0.8% | €485.10 | €485.81 | €482.56 | 174 | |
| €478.98 | +13.18 | +2.8% | €468.28 | €481.34 | €462.73 | 352 | |
| €465.80 | +2.945 | +0.6% | €463.21 | €466.57 | €460.71 | 5 | |
| €462.86 | -7.464 | -1.6% | €463.01 | €468.13 | €456.16 | 5 | |
| €470.32 | +1.46 | +0.3% | €471.26 | €472.45 | €469.89 | 346 | |
| €468.86 | +9.65 | +2.1% | €467.81 | €469.06 | €467.65 | 258 | |
| €459.21 | +15.40 | +3.5% | €459.56 | €460.26 | €455.43 | 12 | |
| €443.81 | -5.034 | -1.1% | €443.81 | €443.81 | €443.81 | 110 | |
| €448.85 | -1.554 | -0.3% | €447.83 | €449.01 | €444.91 | 24 | |
| €450.40 | +0.932 | +0.2% | €450.40 | €450.40 | €450.40 | 0 | |
| €449.47 | +5.114 | +1.2% | €448.82 | €454.19 | €448.74 | 347 | |
| €444.35 | -5.715 | -1.3% | €434.40 | €445.16 | €427.83 | 79 | |
| €450.07 | -5.064 | -1.1% | €450.11 | €450.11 | €449.99 | 101 | |
| €455.13 | +9.173 | +2.1% | €455.13 | €455.13 | €455.13 | 20 | |
| €445.96 | -4.27 | -0.9% | €445.96 | €445.96 | €445.96 | 52 | |
| €450.23 | -2.643 | -0.6% | €450.23 | €450.23 | €450.23 | 193 | |
| €452.87 | +2.374 | +0.5% | €449.99 | €456.90 | €448.22 | 97 | |
| €450.50 | +0.297 | +0.1% | €451.95 | €454.42 | €447.40 | 7 | |
| €450.20 | -0.565 | -0.1% | €450.95 | €451.81 | €449.40 | 15 | |
| €450.77 | -7.509 | -1.6% | €451.20 | €453.66 | €446.46 | 408 | |
| €458.28 | -7.572 | -1.6% | €459.68 | €460.94 | €456.85 | 130 | |
| €465.85 | +1.324 | +0.3% | €465.85 | €465.85 | €465.85 | 0 | |
| €464.52 | +0.331 | +0.1% | €464.84 | €465.07 | €463.24 | 118 | |
| €464.19 | +4.773 | +1.0% | €464.19 | €464.19 | €464.19 | 12 | |
| €459.42 | +3.451 | +0.8% | €458.33 | €459.97 | €458.03 | 120 | |
| €455.97 | +1.317 | +0.3% | €454.21 | €456.34 | €451.04 | 201 | |
| €454.65 | +2.188 | +0.5% | €450.71 | €455.57 | €450.48 | 61 | |
| €452.46 | +11.76 | +2.7% | €446.85 | €457.49 | €445.99 | 51 | |
| €440.70 | -3.23 | -0.7% | €440.70 | €440.70 | €440.70 | 53 | |
| €443.93 | -5.65 | -1.3% | €447.30 | €449.62 | €443.52 | 2 | |
| €449.58 | +5.196 | +1.2% | €449.78 | €454.80 | €444.19 | 165 | |
| €444.39 | -4.726 | -1.1% | €444.39 | €444.39 | €444.39 | 0 | |
| €449.11 | +4.775 | +1.1% | €449.11 | €449.11 | €449.11 | 0 | |
| €444.34 | +4.389 | +1.0% | €442.32 | €445.60 | €440.31 | 116 | |
| €439.95 | -2.754 | -0.6% | €440.72 | €441.30 | €439.95 | 20 | |
| €442.70 | -5.846 | -1.3% | €443.60 | €448.38 | €442.39 | 71 | |
| €448.55 | -13.50 | -2.9% | €449.73 | €450.93 | €448.01 | 129 | |
| €462.05 | -2.727 | -0.6% | €462.95 | €463.12 | €461.84 | 38 | |
| €464.77 | -10.54 | -2.2% | €467.70 | €468.52 | €463.58 | 2 | |
| €475.32 | -1.302 | -0.3% | €475.32 | €475.32 | €475.32 | 70 | |
| €476.62 | +6.039 | +1.3% | €477.75 | €483.44 | €475.98 | 84 | |
| €470.58 | -4.314 | -0.9% | €469.70 | €470.93 | €468.77 | 35 | |
| €474.90 | +6.019 | +1.3% | €471.90 | €477.37 | €470.18 | 136 | |
| €468.88 | +4.068 | +0.9% | €473.06 | €473.06 | €468.18 | 66 | |
| €464.81 | -1.386 | -0.3% | €464.81 | €464.81 | €464.81 | 64 | |
| €466.19 | -6.199 | -1.3% | €467.54 | €468.01 | €462.32 | 126 | |
| €472.39 | +1.598 | +0.3% | €472.44 | €472.44 | €472.04 | 12 | |
| €470.80 | +2.159 | +0.5% | €471.96 | €477.89 | €470.80 | 75 | |
| €468.64 | -0.417 | -0.1% | €469.14 | €469.66 | €468.64 | 83 | |
| €469.05 | -3.536 | -0.7% | €459.66 | €472.36 | €459.48 | 20 | |
| €472.59 | +5.153 | +1.1% | €473.29 | €476.45 | €469.80 | 30 |
Splits
1 split · FWB:VX1 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split |
- Ticker
- Frankfurt:VX1
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Vertex to Participate in Upcoming Investor Conferences
Latest earnings call · Nov 2, 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 23, 2026
American Society of Nephrology Kidney Week 2026
Conference · 23 slides
Latest news
Vertex to Participate in Upcoming Investor Conferences
Nov 4, 2026
Closed €492.92 (+1.3%) on Nov 5, 2026
Vertex Reports Third Quarter 2026 Financial Results
Nov 2, 2026
Closed €481.17 (-2.9%) on Nov 3, 2026
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
Oct 23, 2026
Closed €462.86 (-1.6%) on Oct 26, 2026
Vertex Appoints Daniel Brennan to its Board of Directors
Oct 20, 2026
Closed €459.21 (+3.5%) on Oct 21, 2026
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Oct 9, 2026
Closed €455.13 (+2.1%) on Oct 12, 2026
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Oct 7, 2026
Closed €450.23 (-0.6%) on Oct 8, 2026
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Sep 22, 2026
Closed €452.46 (+2.7%) on Sep 22, 2026
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Sep 15, 2026
Closed €449.11 (+1.1%) on Sep 15, 2026
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Sep 1, 2026
Closed €474.90 (+1.3%) on Sep 1, 2026
Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)
Aug 4, 2026
Closed €411.73 (-1.5%) on Aug 5, 2026
Vertex Pharmaceuticals Incorporated on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 47 in the last 12 months · 340 in all · newest Nov 4, 2026 · oldest 2005
- Calls
- 32 calls with a replay · 32 with a transcript · latest Nov 2, 2026
- Decks
- 20 decks · latest Oct 23, 2026
Where Vertex Pharmaceuticals Incorporated is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VRTX · Home listing | NASDAQ | United States | USD |
| Xetra:VX1 | Xetra | Germany | EUR |
| gettex:VX1 | gettex | Germany | EUR |
| BCBA:VRTX | BCBA | Argentina | ARS |
| Tradegate:VX1 | Tradegate | Germany | EUR |
| LS Exchange:882807 | LS Exchange | Germany | EUR |
| BMV:VRTX | BMV | Mexico | MXN |
| B3:VRTX34 | B3 | Brazil | BRL |
| Lang & Schwarz:882807 | Lang & Schwarz | Germany | EUR |
| LSE:0QZU | LSE | United Kingdom | USD |
| Frankfurt:VX1 · This page | Frankfurt | Germany | EUR |
| EUROTLX:4VRTX | EUROTLX | Italy | EUR |
| BCBA:VRTXD | BCBA | Argentina | USD |
| Milan:1VRTX | Milan | Italy | EUR |
| VIE:VRTX | Vienna | Austria | EUR |
| BIVA:VRTX | BIVA | Mexico | MXN |
| BOATS:VRTX | BOATS | United States | USD |
| Stuttgart:VX1 | Stuttgart | Germany | EUR |
| Dusseldorf:VX1 | Dusseldorf | Germany | EUR |
| Hanover:VX1 | Hanover | Germany | EUR |
| Munich:VX1 | Munich | Germany | EUR |
| BX Swiss:VX1 | BX Swiss | Switzerland | CHF |
| Aquis:VX1D | Aquis | United Kingdom | EUR |
| BCBA:VRTXC | BCBA | Argentina | USD |
| Hamburg:VX1 | Hamburg | Germany | EUR |
| Aquis:VX1D | Aquis | United Kingdom | EUR |
| Turquoise:VRTXN | Turquoise | United Kingdom | USD |
| BCBA:VRTX.CI | BCBA | Argentina | ARS |
Valuation
P/E 32.8× against a median of 18.8×: 9th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $128.8B USD
- P/E
- 32.8×
- EV/sales
- 9.9×
- EV/EBITDA
- 28.4×
- Price/book
- 6.3×
- Gross margin
- 85.5%
- Operating margin
- 33.2%
- Net margin
- 30.7%
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 0.47
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated · NASDAQ:VRTX | US$130.6B | US$128.8B | 32.8× | 9.9× | 28.4× | 6.3× | 30.7% | 0.2× | 0.47 |
| Merck & Company, Inc. · NYSE:MRK | US$329.7B | US$373.8B | 134× | 5.5× | n/a | 7.3× | 3.6% | 1.2× | 0.28 |
| Novartis AG · SIX:NOVN | US$287.4B | US$304.7B | 20.6× | n/a | n/a | 6.2× | n/a | 0.6× | n/a |
| AstraZeneca PLC · LSE:AZN | US$272.1B | US$298.0B | 24.6× | 4.8× | 14.1× | 5.3× | 17.7% | 0.7× | n/a |
| Pfizer, Inc. · NYSE:PFE | US$156.2B | US$207.8B | 38.7× | 3.3× | 9.6× | 1.8× | 6.3% | 0.7× | 0.29 |
| Novo Nordisk A/S Class B · OMXCOP:NOVO_B | US$129.4B | US$142.3B | 7.8× | 2.9× | 5.5× | 4.0× | 33.9% | 0.6× | n/a |
| Bristol-Myers Squibb Company · NYSE:BMY | US$120.2B | US$151.3B | 13.0× | 3.0× | n/a | 5.1× | 18.5% | 1.9× | 0.26 |
| Sanofi SA · EURONEXT:SAN | US$111.7B | US$126.9B | 14.6× | 2.3× | 4.7× | 1.4× | 13.9% | 0.3× | n/a |
| GSK plc · LSE:GSK | US$96.63B | US$123.8B | 17.0× | 2.8× | 9.3× | 3.9× | 13.0% | 1.3× | n/a |
| argenx SE · EURONEXT:ARGX | US$58.86B | US$53.72B | 22.8× | 6.5× | n/a | 7.0× | 31.4% | 0.0× | n/a |
| Roche Holding Ltd · SIX:RO | US$51.16B | US$77.45B | 3.3× | 1.1× | 2.9× | 1.3× | 20.9% | 1.0× | n/a |
| Median of the others | US$124.8B | US$146.8B | 18.8× | 3.0× | 7.4× | 4.6× | 17.7% | 0.7× | 0.28 |
Forecasts
20 strong buy · 6 buy · 4 hold · 1 sell · 1 strong sell · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 592.36 USD · Analysts' mean
- EPS, year to Dec 2026
- 18.12 · 25 analysts
- Revenue, year to Dec 2026
- 13.25B · 27 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Reshma Kewalramani | Chief Executive Officer and President |
| Charles Wagner | Executive Vice President and Chief Operating & Financial Officer |
| Joy Liu | Executive Vice President and Chief Legal Officer |
| Vertex Pharmaceuticals Incorporated | Investor Relations |
| Amit K. Sachdev | Executive Vice President, Chief Patient and External Affairs Officer |
| Carmen Bozic | Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer |
| Duncan McKechnie | Executive Vice President and Chief Commercial Officer |
| E. Morrey Atkinson | Executive Vice President and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations |
| Jasper van Grunsven | Executive Vice President and Chief Pain and New Product Planning Officer |
| Mark Bunnage | Executive Vice President and Chief Scientific Officer |
| Nia Tatsis | Executive Vice President and Chief Product Affairs Officer |
| Jeffrey Leiden | Executive Chairman |
Board
| Director | Role |
|---|---|
| Jeffrey Leiden | Executive Chairman |
| Alan Garber | Director |
| Bruce Sachs | Director |
| Daniel J. Brennan | Director |
| Diana McKenzie | Director |
| Jennifer Schneider | Director |
| Lloyd Carney | Director |
| Michel Lagarde | Director |
| Nancy Thornberry | Director |
| Sangeeta N. Bhatia | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2026 Earnings Call | Mon, Nov 02, 2026 · 4:30 PM ET | Replay |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2026 Earnings Call | Mon, Aug 03, 2026 · 4:30 PM ET | Replay |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2026 Earnings Call | Mon, May 04, 2026 · 4:30 PM ET | Replay |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2025 Earnings Call | Thu, Feb 12, 2026 · 4:30 PM ET | Replay |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2025 Earnings Call | Mon, Nov 03, 2025 · 4:30 PM ET | Replay |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2025 Earnings Call | Mon, Aug 04, 2025 · 4:30 PM ET | Replay |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q1 2025 Earnings Call | Mon, May 05, 2025 · 4:30 PM ET | Replay |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 2024 Earnings Call | Mon, Feb 10, 2025 · 4:30 PM ET | Replay |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 2024 Earnings Call | Mon, Nov 04, 2024 · 4:30 PM ET | Replay |
| Vertex Pharmaceuticals (NASDAQ:VRTX) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 4:30 PM ET | Replay |
All 32 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 2, 2026 · After close | −4.0% |
| Q2 2026 | Aug 3, 2026 · After close | +1.7% |
| Q1 2026 | May 4, 2026 · After close | −1.3% |
| Q4 2025 | Feb 12, 2026 · After close | +5.7% |
| Q3 2025 | Nov 3, 2025 · After close | −1.0% |
| Q2 2025 | Aug 4, 2025 · After close | −20.6% |
| Q1 2025 | May 5, 2025 · After close | −10.0% |
| Q4 2024 | Feb 10, 2025 · After close | −3.1% |
| Q3 2024 | Nov 4, 2024 · After close | +5.7% |
| Q2 2024 | Aug 1, 2024 · After close | −2.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 6, 2024 · After close | +1.9% |
| Q4 2023 | Feb 5, 2024 · After close | −3.0% |
| Q3 2023 | Nov 6, 2023 · After close | −1.9% |
| Q2 2023 | Aug 1, 2023 · After close | +3.1% |
| Q1 2023 | May 1, 2023 · After close | +0.3% |
| Q4 2022 | Feb 7, 2023 · After close | −4.9% |
| Q3 2022 | Oct 27, 2022 · After close | +9.0% |
| Q2 2022 | Aug 4, 2022 · After close | +4.8% |
| Q1 2022 | May 5, 2022 · After close | −4.7% |
| Q4 2021 | Jan 26, 2022 · After close | +0.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| American Society of Nephrology Kidney Week 2026 | Conference | 23 slides | Oct 23, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 21 slides | Aug 3, 2026 |
| Merger or Acquisition (July 2026) | Merger or acquisition | 17 slides | Jul 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 19 slides | May 4, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 21 slides | January 2026 |
| American Society of Nephrology Kidney Week 2025 | Conference | 42 slides | Nov 8, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 20 slides | Nov 3, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 20 slides | May 5, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 19 slides | Feb 10, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 21 slides | Nov 4, 2024 |
All 20 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2024 Earnings Presentation | Earnings | 19 slides | Aug 1, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 22 slides | May 6, 2024 |
| Q4 2023 Earnings Presentation | Earnings | 27 slides | Feb 5, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 20 slides | Nov 6, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 20 slides | Aug 1, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 21 slides | May 1, 2023 |
| Q4 2022 Earnings Presentation | Earnings | 21 slides | Feb 7, 2023 |
| Q3 2022 Earnings Presentation | Earnings | 18 slides | Oct 27, 2022 |
| FY2018 Earnings Presentation | Earnings | 13 slides | Feb 5, 2019 |
| Q4 2017 Earnings Presentation | Earnings | 24 slides | Jan 31, 2018 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.0B | 11.0B | 9.87B | 8.93B | 7.57B | 6.21B | 4.16B | 3.05B | 2.49B | 1.70B |
| Cost of revenue | 1.65B | 1.53B | 1.26B | 1.08B | 904.2M | 736.3M | 547.8M | 409.5M | 275.1M | 210.5M |
| Gross profit | 10.3B | 9.49B | 8.61B | 7.85B | 6.67B | 5.47B | 3.62B | 2.64B | 2.21B | 1.49B |
| Research and development | 3.91B | 3.63B | 3.16B | 2.54B | 3.05B | 1.83B | 1.75B | 1.42B | 1.32B | 1.05B |
| Selling, general and administrative | 1.75B | 1.46B | 1.14B | 944.7M | 840.1M | 770.5M | 658.5M | 557.6M | 496.1M | 432.8M |
| Operating income | 4.17B | -232.9M | 3.83B | 4.31B | 2.78B | 2.86B | 1.20B | 635.1M | 123.2M | 9.94M |
| Depreciation and amortization | 209.8M | 207.2M | 181.3M | 148.3M | 125.6M | 109.5M | 106.9M | 72.4M | 61.4M | 61.4M |
| EBITDA | 4.38B | -25.7M | 4.01B | 4.46B | 2.91B | 2.97B | 1.30B | 707.6M | 184.6M | 71.3M |
| Interest expense | 13.3M | 30.6M | 44.1M | 54.8M | 58.2M | 58.5M | 72.5M | 69.3M | ||
| Income before tax | 4.64B | 248.5M | 4.38B | 4.23B | 2.73B | 3.12B | 1.39B | 600.2M | -15.7M | -67.4M |
| Income tax | 690.0M | 784.1M | 760.2M | 910.4M | 388.3M | 405.2M | 218.1M | -1.49B | -107.3M | 16.7M |
| Net income | 3.95B | -535.6M | 3.62B | 3.32B | 2.34B | 2.71B | 1.18B | 2.10B | 263.5M | -112.1M |
| Earnings per share, basic | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | 8.24 | 1.06 | -0.46 |
| Earnings per share, diluted | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | -0.46 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.08B | 4.57B | 10.4B | 10.5B | 6.79B | 5.99B | 3.11B | 2.65B | 1.67B | 1.18B |
| Short-term investments | 1.52B | 1.55B | 849.2M | 274.5M | 729.9M | 670.7M | 699.0M | 518.1M | 423.3M | |
| Receivables | 2.05B | 1.61B | 1.56B | 1.44B | 1.14B | 885.4M | 633.5M | 409.7M | 281.3M | 200.4M |
| Inventory | 1.69B | 1.21B | 738.8M | 460.6M | 353.1M | 280.8M | 167.5M | 124.4M | 111.8M | 77.6M |
| Current assets | 11.2B | 9.60B | 14.1B | 13.2B | 9.56B | 8.13B | 4.82B | 3.84B | 2.65B | 1.83B |
| Property, plant and equipment | 745.1M | 812.0M | 789.4M | 698.4M | ||||||
| Goodwill | 1.09B | 1.09B | 1.09B | 1.09B | 1.00B | 1.00B | 1.00B | 50.4M | 50.4M | 50.4M |
| Total assets | 25.6B | 22.5B | 22.7B | 18.2B | 13.4B | 11.8B | 8.32B | 6.25B | 3.55B | 2.90B |
| Accounts payable | 461.7M | 413.0M | 364.9M | 303.9M | 195.0M | 155.1M | 87.6M | 111.0M | 74.0M | 61.5M |
| Current liabilities | 3.86B | 3.56B | 3.55B | 2.74B | 2.14B | 1.88B | 1.33B | 1.12B | 807.3M | 792.5M |
| Long-term debt | 0 | |||||||||
| Total debt | 0 | |||||||||
| Total liabilities | 6.98B | 6.12B | 5.15B | 4.24B | 3.33B | 3.06B | 2.23B | 1.81B | 1.50B | 1.56B |
| Shareholders' equity | 18.7B | 16.4B | 17.6B | 13.9B | 10.1B | 8.69B | 6.09B | 4.44B | 2.03B | 1.16B |
| Shares outstanding | 254.0M | 256.9M | 257.7M | 257.0M | 254.5M | 259.9M | 259.0M | 255.2M | 253.3M | 248.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 3.63B | -492.6M | 3.54B | 4.13B | 2.64B | 3.25B | 1.57B | 1.27B | 844.9M | 236.1M |
| Capital spending | -437.6M | -297.7M | -200.4M | -204.7M | -235.0M | -259.8M | -75.4M | -95.4M | -99.4M | -56.6M |
| Free cash flow | 3.19B | -790.3M | 3.34B | 3.93B | 2.41B | 2.99B | 1.49B | 1.17B | 745.5M | 179.5M |
| Cash from investing | -945.4M | -3.77B | -3.14B | -321.1M | -340.9M | 99.4M | -1.24B | -202.2M | -483.3M | 51.2M |
| Cash from financing | -2.26B | -1.49B | -562.2M | -67.7M | -1.48B | -505.3M | 126.8M | -71.2M | 68.4M | 133.3M |
| Share buybacks | -2.02B | -1.18B | -427.6M | 0 | -1.43B | -539.1M | -186.0M | -350.0M | 0 | 0 |
| Change in cash | 515.6M | -5.80B | -139.7M | 3.71B | 811.2M | 2.87B | 462.4M | 990.7M | 435.8M | 415.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 2, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 20, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 1, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 31, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 6, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| S-8 POS | May 13, 2026 | Offer document | SEC |
| S-8 POS | May 13, 2026 | Offer document | SEC |
| S-8 POS | May 13, 2026 | Offer document | SEC |
| S-8 POS | May 13, 2026 | Offer document | SEC |
| S-8 POS | May 13, 2026 | Offer document | SEC |
| S-8 POS | May 13, 2026 | Offer document | SEC |
| S-8 POS | May 13, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 13, 2026 | Offer document | SEC |
| 8-K · Current report | May 13, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Apr 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 2, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 2, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 2, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Mar 27, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 13, 2026 | Annual report | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 11, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Vertex Pharmaceuticals Incorporated’s releases · as of Oct 31, 2026
- Common shares
- 253,537,674
- Fully diluted
- 253,537,674
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 253,537,674 | Oct 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 31, 2026 | 253,537,674 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| William Young Other companies: Autolus Therapeutics plc (Chair of the Nominating and Governance Committee, Member of the Research & Development Committee · Since at least Mar 18, 2026); Praxis Precision Medicines, Inc. (Director · Since at least Oct 15, 2020); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 26, 2022 · Past); NanoString Technologies Inc (Director · Jun 25, 2013 – May 6, 2024 · Past); BioMarin Pharmaceutical Inc. (Director · Sep 22, 2010 – Jun 10, 2015 · Past); Human Genome Sciences Inc (Director · Apr 27, 2006 – Apr 27, 2006 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – May 22, 2014 · Past); Biogen Inc. (Director · Jan 9, 2006 – Jan 8, 2014 · Past) | Director · May 7, 2014 – Jun 1, 2020 · Past |
| Nancy J. Wysenski Other companies: Cytokinetics, Incorporated (Director · Since at least Nov 20, 2020); Provention Bio Inc (Director · May 19, 2020 – Apr 27, 2023 · Past); Dova Pharmaceuticals Inc (Director · Jun 25, 2018 – Nov 12, 2019 · Past); Inovio Pharmaceuticals, Inc. (Director · Mar 4, 2015 – May 13, 2016 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 10, 2014 – Jun 10, 2019 · Past); Alkermes plc (Director · May 15, 2013 – Jul 7, 2023 · Past); Indevus Pharmaceuticals Inc (Director · Feb 23, 2009 – Feb 23, 2009 · Past); North American Scientific Inc (Director · May 3, 2006 – Apr 29, 2008 · Past) | EVP, Chief Commercial Officer · Dec 9, 2009 – May 14, 2012 · Past |
| Dennis L Winger Other companies: Pacira BioSciences, Inc. (Director · Sep 11, 2013 – Jun 14, 2017 · Past); Nektar Therapeutics (Director · Dec 8, 2009 – Aug 17, 2018 · Past); Accuray Incorporated (Director · Sep 4, 2009 – Nov 30, 2017 · Past); Cell Genesys Inc (Director · Jun 30, 2006 – Oct 14, 2009 · Past); Cephalon Inc (Director · May 17, 2006 – Oct 14, 2011 · Past); Heron Therapeutics, Inc. (Director · Mar 20, 2006 – Aug 11, 2006 · Past); Applied Biosystems Inc. (Senior Vice President and CFO · Jan 25, 2006 – Nov 20, 2008 · Past) | Director · Jul 6, 2009 – Mar 9, 2012 · Past |
| Charles A Sanders Other companies: LipoScience Inc (Director · Jan 24, 2013 – Jan 30, 2013 · Past); BioCryst Pharmaceuticals, Inc. (Director · Dec 8, 2009 – Feb 29, 2016 · Past); Cephalon Inc (Director · May 12, 2009 – May 20, 2010 · Past); Genentech Inc (Director · Mar 26, 2009 – Mar 26, 2009 · Past); Icagen Inc (Director · Mar 5, 2009 – Sep 2, 2011 · Past); Albireo Pharma Inc (Director · Mar 3, 2009 – Mar 8, 2012 · Past) | Director · May 4, 2009 – Jun 1, 2010 · Past |
| Stuart Arbuckle Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Jan 8, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Jan 5, 2026); Rhythm Pharmaceuticals, Inc. (Director · Since at least Jul 23, 2019); ImmunoGen Inc (Director · Jan 23, 2018 – Feb 12, 2024 · Past); Dare Bioscience, Inc. (Director · Jun 22, 2016 – Jan 3, 2017 · Past) | EVP, COO · Since at least May 25, 2016 |
| Christiana Stamoulis Other companies: Mallinckrodt Inc (President and CFO · Since at least Sep 22, 2025); Incyte Corporation (EVP & Chief Financial Officer · Since at least Feb 11, 2019); Hologic Inc (Director · Since at least Nov 1, 2011); Cogent Biosciences, Inc. (President & C.F.O. · Mar 28, 2018 – Mar 28, 2018 · Past) | SVP, Corp Strategy & Bus Devlp · Oct 6, 2010 – Jul 30, 2013 · Past |
| Daniel Brennan Other companies: Crinetics Pharmaceuticals, Inc. (Member of the Board of Directors · Since at least Nov 4, 2026); Madrigal Pharmaceuticals, Inc. (Director · Since at least Aug 1, 2025); Waters Corporation (Director · Since at least Nov 23, 2022); Boston Scientific Corporation (EVP and CFO · Jan 1, 2023 – Feb 18, 2025 · Past) | Director · Since at least Oct 20, 2026 |
| Jeffrey A Chodakewitz Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Apr 13, 2021); Schrodinger, Inc. (Board Member · Since at least Apr 30, 2020); Adicet Bio, Inc. (Director · Since at least Aug 14, 2018); Tetraphase Pharmaceuticals Inc (Director · Jun 12, 2014 – Jun 10, 2019 · Past) | EVP · Jul 15, 2014 – Apr 1, 2018 · Past |
| Terrence C Kearney Other companies: AveXis Inc (Director · Feb 10, 2016 – May 15, 2018 · Past); Innoviva, Inc. (Director · Oct 30, 2014 – Apr 24, 2015 · Past); Acceleron Pharma Inc (Director · Jul 14, 2014 – Nov 19, 2021 · Past); Hospira Inc (Chief Operating Officer · May 17, 2006 – Dec 15, 2010 · Past) | Director · May 17, 2011 – May 1, 2024 · Past |
| Wayne Riley Other companies: Heartflow, Inc. (Member of the Board of Directors · Since at least Aug 7, 2025); COMPASS Pathways Plc (Director · Since at least Jan 1, 2022); HCA Healthcare, Inc. (Director · Since at least Jan 1, 2012); Pinnacle Financial Partners, Inc. (Director · Feb 28, 2011 – Feb 28, 2013 · Past) | Director · Jul 9, 2010 – Jun 1, 2015 · Past |
All 58 people
| Person | Seat |
|---|---|
| Diana L. McKenzie Other companies: Agilon Health, Inc. (Director · Since at least Feb 17, 2023); MetLife, Inc. (Director · Since at least Apr 1, 2022); Change Healthcare Inc (Director · Apr 25, 2022 – Oct 3, 2022 · Past) | Director · Since at least Apr 14, 2022 |
| Elaine Ullian Other companies: Hologic Inc (Director · Oct 22, 2007 – Nov 13, 2017 · Past); Valeant Pharmaceuticals International Inc (Director · Jan 1, 2006 – Jan 1, 2008 · Past); Thermo Fisher Scientific Inc (Director · Dec 31, 2005 – May 22, 2019 · Past) | Director · Jun 1, 2006 – Jun 1, 2019 · Past |
| Eve Elizabeth Slater Other companies: Aceragen Inc. (Director · Jun 16, 2010 – Jun 8, 2015 · Past); Phase Forward Inc (Director · Feb 26, 2007 – Feb 26, 2007 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 25, 2007 · Past) | Director · Mar 23, 2006 – Jun 1, 2007 · Past |
| Jeffrey Leiden Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Quest Diagnostics Incorporated (Director · Jul 1, 2015 – May 29, 2018 · Past) | Executive Chairman · Since at least Jul 21, 2015 |
| Jennifer Schneider Other companies: Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Health Assurance Acquisition Corp (Director · Nov 12, 2020 – Nov 12, 2020 · Past); Livongo Health Inc (President · Jul 24, 2019 – Oct 30, 2020 · Past) | Director · Since at least May 15, 2024 |
| Margaret G McGlynn Other companies: Novavax, Inc. (Director · Since at least Dec 7, 2020); Amicus Therapeutics Inc (Director · Since at least Oct 28, 2009); Air Products and Chemicals, Inc. (Director · Dec 31, 2005 – Sep 30, 2020 · Past) | Director · May 12, 2011 – May 1, 2023 · Past |
| Michel Lagarde Other companies: West Pharmaceutical Services, Inc. (be President and Chief Executive Officer · Since at least Jun 1, 2026); Thermo Fisher Scientific Inc (Executive Vice President · Since at least Aug 29, 2017); Patheon N.V. (President · Jul 20, 2016 – Aug 29, 2017 · Past) | Director · Since at least Oct 5, 2023 |
| David T Howton Other companies: Solid Biosciences Inc. (Chief Operating Officer · Since at least Dec 2, 2022); Sarepta Therapeutics, Inc. (EVP, General Counsel · Nov 5, 2012 – Jun 22, 2020 · Past) | SVP & Chief Legal Officer · Aug 29, 2011 – Feb 2, 2012 · Past |
| John Alam Other companies: CervoMed Inc. (Co-Founder and Chief Executive Officer · Since at least Aug 16, 2023); Pathfinder Cell Therapy Inc (Director · Sep 2, 2011 – Sep 2, 2011 · Past) | EVP, Med. Dev. Group & CMO · Dec 20, 2005 – Oct 1, 2008 · Past |
| Jonathan Biller Other companies: Agios Pharmaceuticals, Inc. (Chief Financial Officer · Dec 3, 2019 – Mar 1, 2022 · Past); Celgene Corporation (EVP AND GENERAL COUNSEL · Jul 3, 2018 – Nov 20, 2019 · Past) | EVP and Chief Legal Officer · Since at least Sep 19, 2022 |
| Lloyd Carney Other companies: Visa Inc. (Director · Since at least Jan 23, 2024); Grid Dynamics Holdings, Inc. (Director · Since at least Nov 14, 2023) | Director · Since at least May 1, 2024 |
| Matthew Emmens Other companies: Bristol-Myers Squibb Company (Director · Feb 21, 2017 – Mar 31, 2021 · Past); Incyte Corporation (Director · May 23, 2006 – May 22, 2008 · Past) | Director · Jun 1, 2006 – Jun 1, 2012 · Past |
| Nancy A. Thornberry Other companies: Denali Therapeutics Inc. (Director · Since at least Jan 8, 2021); Schrodinger, Inc. (Board Member · Since at least Feb 5, 2020) | Director · Since at least Dec 5, 2023 |
| Ourania Tatsis Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Verve Therapeutics Inc (Director · Since at least Jun 26, 2024) | EVP, Chief Reg. & Quality Off. · Since at least Oct 1, 2019 |
| Paul M Silva Other companies: Rapport Therapeutics, Inc. (Director · Since at least Nov 7, 2024); Nurix Therapeutics, Inc. (Director · Since at least Oct 1, 2021) | SVP & Chief Accounting Officer · Sep 29, 2008 – Feb 26, 2021 · Past |
| Suketu Upadhyay Other companies: Incyte Corporation (EVP & Chief Financial Officer · Since at least May 4, 2026); Zimmer Biomet Holdings, Inc. (Exec VP, CFO · Since at least Feb 25, 2021) | Director · Since at least May 18, 2022 |
| Alan Garber Other companies: Exelixis, Inc. (Director · May 2, 2006 – Mar 21, 2024 · Past) | Director · Since at least Jun 8, 2017 |
| Amit K. Sachdev Other companies: Eiger Biopharmaceuticals Inc (Director · Apr 15, 2019 – Mar 1, 2023 · Past) | Executive Vice President, Chief Patient and External Affairs Officer · Since at least Jul 23, 2007 |
| Bastiano Sanna Other companies: Adicet Bio, Inc. (Director · Dec 1, 2020 – Aug 14, 2023 · Past) | EVP, Cell & Genetic Therapies · Feb 3, 2021 – May 5, 2023 · Past |
| Charles F Wagner Jr Other companies: TJX Companies, Inc. (the) (Director · Since at least Sep 20, 2023) | EVP, CO & FO · Since at least Apr 1, 2022 |
| Edward Morrow Atkinson III Other companies: 89bio Inc (Director · Since at least Feb 17, 2022) | EVP, Chief Technical Ops. Off. · Since at least Aug 29, 2023 |
| Joshua Boger Other companies: CervoMed Inc. (Chair Of The Board · Since at least Feb 7, 2024) | Director · Feb 2, 2006 – Jun 8, 2017 · Past |
| Kenneth L Horton Other companies: Senseonics Holdings, Inc. (GC & Corp. Development Advisor · Since at least Mar 5, 2021) | EVP & Chief Legal Officer · Jun 11, 2012 – Nov 17, 2014 · Past |
| Lisa Kelly Other companies: Nitromed Inc (V.P., Human Resources · Jan 6, 2006 – Mar 30, 2006 · Past) | SVP, Human Resources · Jul 12, 2007 – Feb 5, 2013 · Past |
| Michael Parini Other companies: Biogen Inc. (Chief Legal Officer · Since at least Jul 15, 2026) | EVP, Chief Adm, Leg & BD Off · Jan 4, 2016 – Feb 24, 2021 · Past |
| Reshma Kewalramani Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Sep 16, 2021 – Jun 12, 2024 · Past) | Chief Executive Officer and President · Since at least Apr 1, 2018 |
| Susie Lisa Other companies: Crinetics Pharmaceuticals, Inc. (Senior Vice President, Investor Relations · Since at least Nov 4, 2026) | Investor Relations · May 5, 2025 – Nov 4, 2026 · Past |
| Yuchun Lee Other companies: Unica Corp (President, CEO & Chairman, Director · Sep 6, 2006 – Sep 29, 2010 · Past) | Director · Sep 14, 2012 – May 1, 2023 · Past |
| Antoinette Paone | Chief Development Officer and Head of Regulatory Affairs · Jan 29, 2026 – Nov 5, 2026 · Past |
| Bruce Sachs | Director · Since at least Apr 14, 2022 |
| Carmen Bozic | Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer · Since at least Oct 1, 2019 |
| Charles Wagner | Executive Vice President and Chief Operating & Financial Officer · Since at least Sep 1, 2026 |
| David Altshuler | EVP, Chief Scientific Officer · Since at least May 23, 2012 |
| Duncan McKechnie | Executive Vice President and Chief Commercial Officer · Since at least Jul 1, 2025 |
| E. Morrey Atkinson | Executive Vice President and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations · Since at least Nov 5, 2026 |
| Eugene Cordes | Director · Jun 1, 2009 – Mar 17, 2011 · Past |
| Jasper van Grunsven | Executive Vice President and Chief Pain and New Product Planning Officer · Since at least Sep 1, 2026 |
| Joy Liu | Executive Vice President and Chief Legal Officer · Since at least Mar 2, 2021 |
| Kristen Ambrose | SVP & Chief Accounting Officer · Since at least May 1, 2021 |
| Mark Bunnage | Executive Vice President and Chief Scientific Officer · Since at least Aug 4, 2025 |
| Megan E Pace | SVP, Corp. Communications · Jul 25, 2012 – Nov 17, 2014 · Past |
| Nia Tatsis | Executive Vice President and Chief Product Affairs Officer · Since at least Oct 9, 2025 |
| Richard C Garrison | SVP and Catalyst · Feb 2, 2006 – May 18, 2009 · Past |
| Roger W Brimblecombe | Director · Feb 13, 2006 – Mar 15, 2010 · Past |
| Sangeeta N. Bhatia | Director · Since at least Jun 4, 2015 |
| Thomas Connolly | SVP, Human Resources · Aug 13, 2013 – Dec 12, 2014 · Past |
| Vertex Pharmaceuticals Incorporated | Investor Relations · Since at least Apr 6, 2026 |
| Victor A Hartmann | EVP, Strategic & Corp. Devlp. · Feb 2, 2006 – Jun 4, 2007 · Past |
Log in to ask 6ix AI your own questions about Vertex Pharmaceuticals Incorporated.